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 Sphingolipids are unique lipids that serve numerous functions important in cell 
regulation. Some categories of sphingolipids have also been implicated in the mechanism 
of action of cancer chemotherapeutic drugs, with the hypothesis being that these drugs 
are effective because they alter sphingolipid metabolic pathways to increase the 
production of ceramide, a sphingolipid known to induce cell death. Fenretinide (4-
hydroxyphenylretinamide, 4HPR) is one such drug and has been thought to induce 
apoptosis through an increase of ceramide biosynthesis. However, recent research by W. 
Zheng et.al 2006., has shown that fenretinide instead increases dihydroceramide, which 
has traditionally been regarded as innocuous in cell signaling. This study has explored 
how fenretinide induces cell death via elevation of dihydroceramide and has discovered 
that dihydroceramide and fenretinide are both potent inducers of autophagy, a pathway 
for turnover of cell constituents that can also trigger type II programmed cell death. In 
addition, this analysis has found that after dihydroceramide induces the formation of 
autophagosomes, it seems to be further metabolized to sphinganine and sphinganine 1-
phosphate as indicated by an increase in the quantity of these species and whether or not 
this results in cell death depends on the balance between these highly bioactive toxic 
(sphinganine) versus anti-apoptotic (sphinganine-1-phosphate) compounds. Thus, these 
studies suggest that the mechanism of fenretinide toxicity has many components: 
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elevation of dihydroceramide to induce autophagy as well as changes in sphinganine and 
sphinganine-1-phosphate, with the balance between the latter dictating if the autophagy is 
lethal. 
Introduction 
In order to understand the mechanism of fenretinide toxicity presented, the 
following key concepts will first be discussed: i) sphingolipids, ii) role of  sphingolipids 
in regulating cell proliferation and cell death, iii) autophagy, iv) current opinions on 
autophagic cell death, and v) role of sphingolipids in autophagy.. 
Sphingolipids - Sphingolipids are a family of phospho- and glycolipids found in 
all eukaryotic and some prokaryotic organisms. They are comprised of a sphingoid base 
backbone that may be unmodified, N-acylated, N-methylated, phosphorylated, or 
incorporated into more complex sphingolipids, such as ceramide phosphoinositols 
(yeast), ceramide phosphoethanolamines (insects), and ceramide phosphocholines 
(mammals and other organisms) as well as simple to complex glycosphingolipids (Figure 
1). The biophysical and biochemical properties of this backbone differentiate 
sphingolipids from other lipid species. For example, at a neutral pH the sphingoid 
backbone carries a net positive charge, which is rare among membrane lipids (1). This 
property may be used to explain the relative ease with which sphingoid bases move 
among membrane bilayers, allowing them to influence many aspects of both intracellular 
and extracellular signaling (2). 
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Figure 1. The sphingolipid metabolic pathway. Modified from source (3). 
Figure 1 illustrates the complexity of the sphingolipid metabolic pathway 
depicting the enzymes involved and the intermediates generated as cells metabolize 
sphingolipids and modify the sphingoid base backbone. De novo sphingolipid 
biosynthesis begins with the condensation of serine and palmitoyl-CoA by serine 
palmitoyltransferase to yield 3-ketosphinganine. 3-ketosphinganine reductase then 
reduces 3-ketosphinganine to sphinganine, which is subsequently N-acylated by 
(dihydro)ceramide synthase  yielding dihydroceramide (4). At this point, 
dihydroceramide desaturase introduces a 4,5 trans double bond into dihydroceramide 
forming ceramide (5). These steps take place on the cytosolic face of the ER (5,6). The 
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resulting ceramide can then be transported to the cis Golgi for incorporation into more 
complex sphingolipids (7).  
Figure 1 also displays that this biosynthetic pathway has enzymes that function in 
both the synthesis and turnover pathways. Ceramidases, found in the organelles such as 
the lysosome and the mitochondria, could perform the reverse reaction of ceramide 
synthase and deacylate ceramide to form sphingosine (7). One such enzyme that is found 
in the lysosome is acid ceramidase; it not only converts ceramide to sphingosine in the 
biosynthetic pathway, but can also form sphinganine through the turnover of 
dihydroceramide (1,3). These backbone species, sphingosine and sphinganine may then 
be phosphorylated by sphingosine kinase to yield sphingosine- or sphinganine-1 
phosphate, respectively. This complex metabolic pathway profoundly affects the cell, as 
changes in the natural rheostat of sphingolipid subspecies may serve as a determining 
factor in cell fate decisions. 
Bioactive Sphingolipids - A delicate balance exists between the bioactive 
sphingolipids that activate cell survival and cell death pathways. Because new roles for 
sphingolipids are continuously being discovered, there is still much to be learned about 
how sphingolipids regulate many processes that occur within the cell. Traditionally, 
ceramide, sphinganine, and sphingosine have been considered to be the bioactive 
sphingolipids that induce cell death and growth arrest, while sphingosine- and 
sphinganine-1-phosphate have been regarded as inducers of cell survival and cell 
proliferation (2,8). 
Sphingoid bases, sphingosine and sphinganine, are known to activate many 
signaling pathways that are cytotoxic to cells (2,9-11). Their ability to behave as 
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detergents when trapped in acidic vesicles allows them to induce cell death by acting as 
lysosomotrophic agents, which permeabilize the lysosomal membrane allowing 
lysosomal contents, such as proteases, to be released into the cytosol. These proteases 
inturn serve as upstream activators of well-characterized cell death pathways (12). 
Although sphinganine and sphingosine are cytotoxic to cells, when phosphorlyated by 
sphingosine kinase, they form sphinganine- or sphingosine-1 phosphate respectively, and 
these phosphorylated species promote cell proliferation rather than cell death (2,13). 
Ceramide, one of the most widely studied sphingolipids, is a known inducer of 
apoptosis, type I programmed cell death. (8). Furthermore, the mechanism of action of 
certain chemotherapeutic drugs is hypothesized to result from alterations in the normal 
sphingolipid metabolic pathway to increase the biosynthesis of ceramide within the cell, 
which in turn results in apoptosis. Fenretinide, a chemotherapeutic agent currently in 
clinical trials for breast and many other types of cancers, is one such drug (14). 
Fenretinide is thought to increase ceramide by the coordinate activation of serine 
palmitoyltransferase and ceramide synthase (15,16). A second proposed mechanism for 
fenretinide’s mode of action is thought to involve the production of reactive oxygen 
species (ROS), again resulting in the stimulation of the apoptotic pathway (17).  
However, in previous studies to determine the effect of fenretinide on the de novo 
sphingolipid biosynthetic pathway, it was found that MCF7 breast cancer cells treated 
with fenretinide experienced only a nominal change in ceramide production; whereas, 
dihydroceramide production increased as much as 10-fold, both as the free species and as 
the backbone for dihydroceramide metabolites (2). The distinction between ceramides 
and dihydroceramides was possibly overlooked in previously published studies because 
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ceramide analysis was performed by techniques such as thin layer chromatography (TLC) 
or diacylglycerol kinase assays (DGK), and these techniques cannot readily distinguish 
dihydroceramides from ceramides. The mechanism of dihydroceramide accumulation has 
been investigated and appears to be due to the inhibition of dihydroceramide desaturase 
(2). This finding is significant because dihydroceramide has long been considered to be 
inactive in cell signaling (18). However, the ability of chemopreventive agents, such as 
fenretinide, to induce increases in dihydroceramide leads one to question the bioactive 
status of this molecule. Furthermore, this research identifies a previously uncharacterized 
signaling function for dihydroceramide, the induction of the formation of cytoplasmic 
vacuoles called autophagosomes.  
Autophagy - Translated from the Greek meaning “to eat oneself,” autophagy is an 
intracellular degradation and recycling pathway that is in various forms ubiquitous 
throughout eukaryotic cells. Macroautophagy, which will be referred to as autophagy for 
the remainder of this thesis, allows cells to degrade cytoplasmic organelles and proteins 
to produce amino acids, lipids, sugars, and nucleotides during nutrient poor conditions 
(19,20). Autophagy also provides a way for cells to degrade damaged organelles, thus 
helping cells survive in otherwise cytotoxic situations (21). In recent years mechanisms 
for monitoring the dynamic process of autophagy have provided evidence that this cell 
survival pathway can also result in programmed cell death, which will be discussed in 




Figure 2. Process of Autophagy. Modified from source (25) 
As seen in Figure 2, autophagy is usually triggered by one of the following 
events: nutrient starvation (26), bacterial or viral invasion (27,28), or certain anticancer 
drugs (29-31). Autophagy is mediated by a wide number of signaling pathways, and as 
technologies for monitoring and understading autophagy improve, many more are being 
elucidated (20). Autophagy begins with the isolation of a piece of the endoplasmic 
reticulum or a membrane created from de novo synthesis. This isolated double membrane 
elongates and recruits microtubules-associated protein light chain 3 (LC3) to its surface 
as it surrounds proteins and organelles to be degraded forming the autophagosome. The 
autophagosome subsequently fuses with the lysosome to form the autophagolysosome, 
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whose acidic environment allows for the degradation of the sequestered proteins and 
organelles (25). 
Autophagy and Cell Death - Autophagy is a complex process; in some cases 
autophagy serves a protective role, but in other situations autophagy can result in cell 
death. Autophagic cell death, referred to as type II programmed cell death, is distinct 
from apoptosis, type I cell death, and necrosis, type III cell death. Degradation of 
organelles is one of the first events to occur during autophagy, while the cytoskeleton is 
one of the last items degraded prior to cell death. Whereas, during apoptosis, the 
cytoskeleton collapses almost immediately following induction and the organelles are 
among the last items degraded prior to cell death. Furthermore, necrotic death is 
characterized by an inflammatory response, not present in either autophagy or apoptosis 
(22). However, the distinction between autophagic cell death and apoptotic cell death is 
not always so distinct. There are many shared molecular signaling pathways activated 
during both autophagic and apoptotic cell death (20,32).  
Currently a debate exists over autophagy’s connection to cell death, with 
questions surrounding the idea of whether autophagy alone induces cell death or whether 
cell death processes, like apoptosis, play a role in autophagic cell death. Some believe 
that autophagy triggers apoptosis, while others believe that autophagy and apoptosis can 
occur simultaneously inside a cell (19-22,25). In a recent review, Yoshimori 
acknowledged that there is not an understanding of what autophagy-inducing conditions 
trigger cell death and what conditions trigger cell survival (24). No current hypotheses 
that explain protective and lethal autophagy can be generalized for all autophagy-
inducing treatments (nutrient starvation, viral and bacterial infection, and 
Fluke 9 
chemotherapeutic drug). It is possible that each autophagy-inducing treatment could 
contain its own molecular switch that signals when autophagy is protective or lethal 
(32,33).  
Autophagy is directly linked to cancer and appears to regulate both cell survival 
and cell death (25). Several chemotherupeutic drugs have previously been identified as 
inducers of autophagy and/or autophagic cell death, including temozolomide in several 
malignant glioma cell lines (30) and tamoxifen in MCF7 breast cancer cells (29), 
Furthermore, this study also identifies the chemotherapeutic agent fenretinide as an 
inducer of autophagy and/or autophagic cell death. So, what mechanism do these and 
other chemotherapeutic agents use to convert autophagy from a survival pathway to a 
death pathway? The ultimate goal of this research is to explain whether this life and death 
transition is dependent on the type of sphingolipid mediators produced inside the cell.  
Sphingolipids Induce Autophagy - Because of their unique role in membrane 
organization and structure and their dual role as both cell survival and cell death 
mediators, sphingolipids appear to be unique mediators of autophagy. Furthermore, they 
could potentially be a bioactive mediator that controls the switch from protective to lethal 
autophagy. 
Many studies have elegantly established ceramide’s ability to mediate autophagy 
through the activation of several key molecules. Ceramide induces lethal autophagy 
through the activation of BNIP3, a mitochondrial death associated protein that induces 
autophagy (34). Ceramide also activates lethal autophagy by upregulating beclin1, a gene 
that is necessary for autophagy to occur in cells (29,34). Another sphingolipid mediator 
of autophagy, sphingosine-1-phosphate induces protective autophagy in MCF7 breast 
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cancer cells during times of nutrient starvation (35). We are currently investigating how 
other sphingolipid species, such as dihydroceramide, regulate autophagy following 
treatment with the chemotherapeutic agent, fenretinide. This thesis aims to provide more 
insight into the molecular basis of fenretinide’s role in cell death via a novel ensemble of 
sphingolipid autophagic regulators, as well as, characterize a previously unidentified 
function of dihydroceramide. 
Experimental Procedures 
 
Reagents – C2- Ceramide and C2- Dihydroceramide were purchased from Avanti 
Polar Lipids Inc (Alabaster, AL). C2-Ceramide and C2-Dihydroceramide analogs contain 
a short acyl chain allowing for easy delivery into the cell when complexed with bovine 
serum albumin 1:1 or 2:1 respectively. Tamoxifen and fenretinide (4HPR, retinoic acid p-
hydroxyanilide) were purchased from Sigma (St. Louis, MO). Myriocin (ISP1) was 
purchased from BioMol (Plymouth Meeting, PA). Acid ceramidase siRNA was 
purchased from Dharmacon (Lafayette, CO). The transfection reagent, DharmaFECT®1, 
was purchased from Dharmacon (Lafayette, CO). Dimethylsphingosine was purchased 
from Avanti Polar Lipids (Alabaster, AL). Martine Leipelt constructed the pEGFPC2-
LC3A plasmid. The LC3A cDNA construct was purchased from OriGene (Rockville, 
MD). The pEGFPC2 vector was purchased from Clontech (Mountain View, CA). 
Cell Lines - MCF7 cells were obtained from the ATCC (Manassas, VA) and 
cultured at 37° C in 5% CO2 in Minimal Essential Media (MEM) supplemented with 
10% FBS, 100x nonessential amino acids (0.01%), sodium bicarbonate (1.5 mg/mL), and 
bovine insulin (0.01 mg/mL).  
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Methods to Measure Autophagy - LC3 (microtubule-associated protein light chain 
3) is normally diffusely distributed throughout the cytoplasm, but upon induction of 
autophagy is recruited to the autophagosomal membrane and appears in a punctate 
pattern. When LC3 is tagged with a fluorescent protein, its localization, in the cytoplasm 
or as a part of the autophagosome, can be easily monitored using confocal microscopy. 
For our studies, GFP-LC3 localization was monitored as previously described (23,26). 
MCF7 cells were cultured on coverslips in a 24 well plate at a seeding density of 
3.75 x 105 cells/well 24 hours prior to transfection (GeneJuice®, Novagen) with the GFP-
LC3 plasmid. Following a 24-hour transfection, to allow for expression of the autophagic 
marker, cells were treated with the appropriate treatment as dictated by the experiment. 
Following treatment, cells were fixed using 2% formaldehyde for 12 minutes. The cell 
nuclei were stained with Hoecsht 33342 (Invitrogen, Carlsbad, CA) for 5 minutes at room 
temperature to clearly identify the number of cells for autophagy scoring purposes. 
Coverslips were examined using the Zeiss 510 Confocal Microscope (Thornwood, NY). 
Confocal images were scored to determine the number of cells that contain GFP-
LC3 punctuate vesicles. The following were used as criteria during the scoring process: 
1) Cell patches of 70 or more cells were not scored due to the differing environments of 
periphery and interior cells, and 2) only cells with entire nuclei and cytoplasm in the 
image were scored. 
Cell Death Assay - Cell death was measured by the Wst-1 cell proliferation assay 
(Roche Molecular Biochemicals). MCF7 cells were cultured in a 96 well plate at a 
seeding density of 1 x 104 cells/well for 24 hours prior to treatment. Following treatment, 
the cells were treated with 10 µL of the Wst-1 reagent for one hour. Colormetric analysis 
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Dihydroceramide and fenretinide induce autophagy - Autophagy was monitored 
in MCF7 cells transfected with the GFP-LC3 plasmid. Previous studies illustrated that 
exogenously added C2- ceramide is an inducer of autophagy (29,34), therefore in our 
studies C2- ceramide served as a positive control. Punctuate GFP-LC3 autophagosomes 
were observed when cells were treated with C2- ceramide (25 µM, 24 hours). 
Quantitatively, 17% of the total cells scored contained autophagosomes (Figure 3). 
Surprisingly, when MCF7 cells were treated with C2- dihydroceramide (25 µM, 24 
hours), autophagy was also observed (Figure 3), and 16% of the scored cells contained 
GFP-LC3 tagged autophagosomes. As can be seen in Figure 3, MCF7 cells treated with 
C2- dihydroceramide resulted in an approximate 4-fold increase in autophagy when 
compared to its respective BSA control (2:1).  
The formation of punctate autophagosomal vesicles following treatment with 
exogenous C2- dihydroceramide identifies a previously uncharacterized signaling 
function for this previously reported inert molecule. Furthermore, the ability of C2-
dihydroceramide to induce autophagosome formation prompted us to investigate the 
ability of fenretinide (4HPR) treatment to induce autophagosome formation in MCF7 
cells, since, as previously discussed, 4HPR treatment leads to an increase in 
dihydroceramide in MCF7 cells (2). 
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Figure 3. Effect of dihydroceramide on autophagy.  Cells were cultured for autophagy analysis as 
described in “Experiment Procedures.” Following transfection with the GFP-LC3 plasmid, MCF7 cells 
were treated with C2- Ceramide (25 µM) or C2- Dihydroceramide (25 µM), complexed with BSA in 1:1 or 
2:1 ratio respectively for 24 hours. The punctuate vesicles mark the presence of autophagosomes. The 
images shown are representative samples of multiple independent experiments. Autophagic cells were 
quantified as described in “Experimental Procedures.”  
 
Autophagy was monitored in MCF7 cells treated with fenretinide as described 
above. Tamoxifen, another anti-cancer agent and known inducer of autophagy in MCF7 
cells (36), served as the positive control in this experiment. As can be seen in Figure 4, 
cellular treatment with tamoxifen (1 µM) induced autophagy in 17% of observed cells 
after 24 hours. Furthermore, cellular treatment with 4HPR (10 µM) also resulted in the 
formation of autophagosomes (Figure 4). Following 24 hours of 4HPR (10 µM) 
treatment, 17% of scored cells contained autophagosomes, resulting in an approximate 4-
fold increase in autophagy when compared to control cells. Therefore, our results not 
only confirm tamoxifen’s ability to induce autophagy, but also identify 4HPR as a novel 
inducer of autophagy.  
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Taken together, these results suggest that 4HPR-mediated autophagy may be 
dependent on intracellular increases in dihydroceramide (2). Therefore, we next 
investigated whether sphingolipid biosynthesis was necessary for 4HPR-induced 
autophagy.  
 
Figure 4. Effect of fenretinide on autophagy. Cells were cultured for autophagy analysis as described in 
“Experimental Procedures.” Twenty-four hours after transfection with GFP-LC3 plasmid, MCF7 cells were 
treated with 4HPR (10 µM) or Tamoxifen (1 µM). The punctuate vesicles indicate the presence of 
autophagosomes. The images shown are representative samples of multiple independent experiements. 
Autophagic cells were quantified as described in “Experimental Procedures.”   
 
Sphingolipid biosynthesis is necessary for fenretinide-induced autophagy and 
fenreitnide cytotoxicity - ISP1 inhibits the first enzyme in the sphingolipid pathway, 
serine palmitoyltransferase, thus blocking de novo synthesis and subsequent 
dihydroceramide production (37). Treating cells with ISP1 allowed us to determine the 
effect of sphingolipid biosynthesis on 4HPR-induced autophagy. MCF7 cells treated with 
ISP1 (1 µM, 25 hours) alone did not result in the formation of autophagosomes (Figure 
5a). In agreement with the previous finding, punctuate autophagosomes were observed 
following 4HPR treatment alone, with 13% of scored cells containing autophagosomes. 
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In contrast, MCF7 cells pre-treated with ISP1 (1 µM, 25 hours) for one hour prior to 
4HPR (10 µM, 24 hours) treatment resulted in reduced levels of autophagy, in which 
only 5% of the cells contained autophagosomes, and this finding was consistent with the 
basal level of autophagy found in control cells (Figure 5a). These results led us to 
conclude that de novo sphingolipid biosynthesis, and possibly the production of 
dihydroceramide is necessary for 4HPR-induced autophagy.  
The requirement of sphingolipids biosynthesis in 4HPR-induced autophagy 
(Figure 5a) prompted us to investigate whether the cytotoxicity of 4HPR was also 
dependent on sphingolipid biosynthesis. Cell viability analysis revealed that 4HPR 
treatment alone resulted in a 22% decrease in cell viability after 48 hours. However, upon 
the inhibition of sphingolipid biosynthesis with ISP1 pre-treatment, cell viability 
decreased only 7% following 48 hours of 4HPR treatment (Figure 5b). Taken together, 
these results suggests that de novo sphingolipid biosynthesis is necessary for both 4HPR-







Figure 5. Sphingolipid de novo synthesis is necessary for fenretinide induce autophagy and cause cell 
death. A. Cells were cultured for autophagy analysis as described in “Experimental Procedures.” Twenty-
four hours after transfection, cells were pre-treated with ISP1 (1 µM) for 1 hour prior to treatment with 
4HPR (10 µM). The punctuate vesicles indicate the presence of autophagosomes. The images shown are 
representative of multiple independent experiments Images were scored as described in the “Experimental 
Procedures.”  
B. Cells were for viability analysis as described in ‘Experimental Procedures.’ MCF7 cells were pre-treated 
with ISP1 (1 µM) for 1 hour prior to treatment with 4HPR (10 µM). Forty-eight hours after 4HPR 
treatment, Wst1 reagent was added and colormetric analysis was performed following one-hour incubation 
at 37ºC. All measurements have been normalized to control cells. 
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Dihydroceramide turnover in the autophagolysosome contributes to fenretinide 
cytotoxicity.- After fenretinide induced dihydroceramide accumulation mediates the 
formation of autophagosomes, dihydroceramide seems to be further metabolized to 
sphinganine and sphinganine 1-phosphate, as indicated by an increase in the quantity of 
these species in a previous study (2). The cytotoxicity of 4HPR is hypothesized to depend 
on the balance between these highly bioactive toxic (sphinganine) versus anti-apoptotic 
(sphinganine-1-phosphate) compounds.  
Sphinganine may be produced from the hydrolysis of the accumulated 
dihydroceramide by acid ceramidase within the autophagolysosome, which presumably 
acquired lysosomal sphingolipids hydrolases upon autophagosomal and lysosomal fusion 
(37). Since sphinganine is known to be a toxic, lysosmotrophic agent (11,12), 
accumulation of this sphingoid base should result in 4HPR cytotoxicity or lethal 
autophagy. Furthermore, if sphinganine accumulation is due to the turnover of 
dihydroceramide rather than de novo synthesis and if sphinganine is involved in 4HPR 
cytotoxicity, then suppression of acid ceramidase should decrease the cytotoxicity of 
4HPR.  
In order to investigate this idea, MCF7 cells were transfected with acid 
ceramidase siRNA to suppress acid ceramidase activity prior to 4HPR treatment, and cell 
viability was  assessed. Figure 6 displays cellular transfection with acid ceramidase 
siRNA for 72 hours alone results in slight background cell death, when compared to 
control cells that were not transfected. Control cells subjected to 4HPR (10 µM, 48 
hours) treatment experienced appreciable cell death, with a 55% decrease in cell viability 
(Figure 6). In contrast, cells transfected with acid ceramidase siRNA (72 hours) prior to 
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4HPR (10 µM, 48 hours) treatment only experienced a 16% decrease in cell viability 
(Figure 6). These results suggest that the sphinganine accumulation observed in a 
previous study is indeed due to the turnover of dihydroceramide, which inturn contributes 
to the cytotoxic mechanism of 4HPR. 
 
 
Figure 6. Acid ceramidase accounts for a portion of fenretinide cytotoxicity. 
Cells were cultured for cell viability as described in “Experimental Procedures.” MCF7 cells were 
transfected with acid ceramidase (AC) siRNA 24 hours later. 24 hours after transfection cells were treated 
with 10µM fenretinide. 48 hours after fenreitnide treatment and 72 hours after AC siRNA Wst1 reagent 
was added and colormetric analysis was performed following one hour incubation at 37ºC. All 
measurements have been normalized to control cells. 
 
Inhibition of sphingosine kinase increases fenretinide cytotoxicity – A portion of 
the sphinganine produced from dihydroceramide turnover, described above, will 
presumably efflux from the autophagolysosome in a manner analogous to the lysosomal 
degradation of sphingolipids (2). Once effluxed, a portion of this sphinganine will 
become phosphorylated by sphingosine kinase to yield sphinganine 1-phosphate (13), 
owing to the accumulation of this species as noted in a previous study (2). A previously 
published study by Lavieu et. al. found sphingosine 1-phosphate to be an inducer of 
protective autophagy during conditions of nutrient starvation (35). Therefore, if 
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phosphorylation and removal of sphinganine to produce of sphinganine 1-phosphate is 
protective, then inhibition of sphingosine kinase and protective autophagy should 
increase the cytotoxicity of 4HPR.   
In order to investigate this idea, dimethylsphingosine (DMS) was used to inhibit 
sphingosine kinase (38). MCF7 cells treated with 4HPR (10 µM, 48 hours) or DMS (1 
µM and 2.5 µM, 48 hours) alone experienced an approximate 35% decrease in cell 
viability when compared to control cells (Figure 7). However, when MCF7 cells were 
pre-treated with DMS for 1 hour prior to 4HPR treatment, a more rapid, pronounced 
decrease in cell viability was observed, resulting in a 59% and a 77% decrease in cell 
viability following 1 µM and 2.5 µM DMS pre-treatments respectively (Figure 7). These 
results suggest that as sphingosine kinase is inhibited, protective autophagy may also be 
inhibited and result in a 4HPR induced lethal autophagic death.  
 
Figure 7. Inhibition of sphingosine kinase increases the cytotoxicity of fenretinide.  
Cells were cultured for cell viability as described in ‘Experimental Procedures.’ Cells were treated with 
4HPR (10 µM) alone, dimethlysphingsone (DMS) alone (1 µM or 2.5 µM) or pre-treated with DMS (1 µM 
or 2.5 µM) for one hour prior to treatment with 4HPR (10µM). 48 hours after 4HPR treatment Wst1 
reagent was added and colormetric analysis was performed following one hour incubation at 37ºC. All 




Fenretinide is a promising anti-cancer agent currently in clinical trials. 
Furthermore, fenretinide is a known inducer of cell death in many types of cancer cells, 
but the mechanism of its action was not well understood (39). Previously published 
findings have attributed fenretinide’s cytotoxicity to the activation of reactive oxygen 
species and/or increases in ceramide biosynthesis (15-17,40). However, the results 
presented here provide an additional and/or alternative mechanism to explain 
fenretinide’s cytotoxic mode of action. Previously, tandem mass spectrometric analysis, 
as well as, in vitro assays revealed that treatment of MCF7 cells with fenretinide 
increased dihydroceramide species, through the inhibition of dihydroceramide desaturase 
(2), leading us to question dihydroceramide’s published biological inactivity (18) and 
prompting us to explore cell regulation mechanisms in which dihydroceramide may 
participate. Biophysically speaking when compared to ceramides, dihydroceramides have 
a lower dipole potential which results in a decrease packing density within the membrane 
(41). Also, dihydroceramides have a lesser tendency to promote flip-flop or trans bilayer 
movement within the membrane (42), and dihydroceramides have been shown to be less 
likely to form and in some cases inhibitory to membrane channel formation when 
compared with ceramides (43). These differences may explain why dihydroceramide 
does not share many signaling pathways with ceramide, but in spite of these differences, 
this research has identified one cellular process that does allow for participation from 
both ceramide and dihydroceramide – the formation of cytoplasmic vacuoles known as 
autophagosomes as evidenced by GFP-LC3 confocal analysis (Figure 3). 
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In addition to identifying a previously uncharacterized signaling function for 
dihydroceramide, our study has provided the first evidence of a novel autophagic 
pathway induced by fenretinide, differing from previous studies which cited fenretinide’s 
cell death mechanism via induction of apoptosis(15-17). The idea must not be excluded 
that fenretinide-induced autophagy may be occurring simultaneously with the apoptosis 
observed in other studies. However, further evidence is needed to confirm this idea, and 
we hypothesize that if both do occur as a result of fenretinide treatment that the time scale 
for each cell death event is different, with apoptosis occurring on a more rapid time scale 
to eliminate the most sensitive cell populations and autophagy occurring on a slightly 
longer time scale to eliminate more resistant cell populations (44). Nevertheless, our 
results clearly indicate that MCF7 cells undergo autophagy in response to fenretinide 
treatment (Figure 4). 
 When exploring the mechanism of fenretinide induced autophagy, we discovered 
that de novo sphingolipid biosynthesis, notably the production of dihydroceramide, is 
required for both the cytotoxic and autophagic actions of fenretinide, as indicated by cell 
viability and confocal image analysis of fenretinide treated cells following pre-treatment 
with ISP1 (Figure 5). Furthermore, these results suggest that there is a strong possibility 
that this 4HPR-induced autophagy could lead to 4HPR-induced cell death. However, our 
results do not provide ample causation between the independent events of sphingolipid 
dependent fenretinide-induced autophagy and sphingolipid dependent fenretinide 
cytotoxicity, but the results do show a correlation between the two events that should be 
explored further. 
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Further exploration of fenretinide’s mechanism of action involving 
dihydroceramide accumulation, revealed that the turnover of dihydroceramide also plays 
a key role in the fate of cells treated with fenretinide. The results in Figure 6 revealed that 
when acid ceramidase expression and dihydroceramide turnover was suppressed, 
fenretininde cytotoxicity decreased, suggesting that acid ceramidase plays a pivotal role 
in fenretinide-induced cell death in MCF7 cells through the production of a cytotoxic 
sphingoid base, sphinganine. Furthermore, these results implicate sphinganine as a key 
component in fenretinide induced lethal autophagy, through its ability to behave as a 
lysosomotrophic agent (12), which induce cell death by permeablizing the lysosomal 
membrane. This permeablization leads to the release of cell death activators, such as 
cathepsins, into the cytosol. These released proteases may then serve as upstream 
activators of cell death pathways (12).  
Additionally, some of the sphinganine produced from the hydrolysis of 
dihydroceramide will efflux from the autophagolysosome in a manner analogous to the 
lysosomal recycling mechanism of sphingolipids becoming phosphorylated by 
sphingosine kinase to yield sphinganine 1-phosphate (13). This sphinganine 1-phoshate is 
then thought to stimulate a protective autophagic mechanism within the cell, consistent 
with a previously published study (35). Our results in Figure 7 provide further support for 
this notion displaying that when sphingosine kinase is inhibited by DMS, cell viability 
decreases much more quickly and to a much larger extent. The results suggest that the 
prevention of sphinganine 1-phosphate formation blocks the protective autophagic 
mechanism and promotes the lethal autophagic mechanism by disturbing the delicate 
ratio of toxic sphinganine to protective sphinganine 1-phoshate. It is our hypothesis that 
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fenretinide’s cytoxicity is not due to the inhibition of sphingosine kinase but rather to 
insufficient activity of sphingosine kinase to handle the large accumulation of 
sphinganine resulting from the turnvover of dihydroceramide within the 
autophagolysosome. Figure 8 provides a summation of the results of this study and our 
current working model of fenretinide’s mechanism of action within the cell.  
In conclusion, a myriad of recent hypotheses speculate and predict the 
relationship between autophagy and cell death (24,32). The term lethal autophagy used 
throughout this paper does not attempt to differentiate between apoptotic and autophagic 
cell death. In our studies, lethal autophagy simply implies that cells contain 
autophagosomes prior to undergoing cell death, and we are currently unsure if this cell 
death is caspase-dependent or caspase-independent. A study by Lamparska-Przybysz et 
al. suggests that the release of cathepsin B, a protease located in the autophagolysosome, 
serves as a molecular switch between autophagy and either apoptosis or lethal autophagy 
(44). The released cathepsin B cleaves BID and activates caspases, hallmarks of 
apoptosis (45). This idea of a molecular switch that regulates protective and lethal 
autophagy possibly provides an intriguing explanation for the ability of a cell to use 
autophagy as both a cell survival and cell suicide pathway. With respect to our study, 
monitoring cathepsin localization might provide insight into the ability of alterations in 
the ratio of sphinganine and sphinganine-1-phosphate to serve as a molecular switch 
regulating protective and lethal autophagy in 4HPR treated MCF7 cells. Our future goal 
is to further understand the complexities of the molecular basis of fenretinide’s role in 





Figure 8. Proposed mechanism of fenretinide induced autophagy. It is our working hypothesis that 
fenretinide induced dihydroceramide accumulation results in the formation of autophagosomes. After 
formation, the autophagosome fuses with lysosomes where it acquires lysosomal sphingolipid hydrolyases, 
including acid ceramidase. Presumably, the acid ceramidase (AC) will hydrolyze some of the accumulated 
dihydroceramide to sphinganine. The sphinganine has two possible fates: 1) It can efflux from the 
autophagolysosome in a manner analogous to the process that occurs during lysosomal degradation of 
sphingolipids and become phosphorylated (which could result in protective autophagy through the 
formation of sphingosine 1-phosphate (35) ), or 2) Sphinganine can accumulate in the autophagolysosome 
due to insufficient sphingosine kinase activity resulting in autophagolysosomal membrane destabilization 
because of its known ability to behave as a lysosomotrophic agent (12), which in turn results in the release 
of pro-death molecules activating cell death pathways. 
Fenretinide (4HPR), Dihydroceramide (DHCer), Sphinganine (Sa), Sphinganine-1-Phosphate (SaP). 
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